Brokerages forecast that Cooper Companies Inc (NYSE:COO) will post sales of $647.77 million for the current quarter, Zacks reports. Ten analysts have issued estimates for Cooper Companies’ earnings, with estimates ranging from $645.60 million to $650.20 million. Cooper Companies reported sales of $628.10 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.1%. The business is scheduled to report its next quarterly earnings results after the market closes on Thursday, March 5th.

According to Zacks, analysts expect that Cooper Companies will report full-year sales of $2.80 billion for the current year, with estimates ranging from $2.79 billion to $2.81 billion. For the next financial year, analysts expect that the company will report sales of $2.98 billion, with estimates ranging from $2.96 billion to $3.01 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for Cooper Companies.

Cooper Companies (NYSE:COO) last posted its quarterly earnings data on Thursday, December 5th. The medical device company reported $3.30 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.03. The business had revenue of $691.60 million during the quarter, compared to the consensus estimate of $683.83 million. Cooper Companies had a net margin of 17.59% and a return on equity of 17.38%. The company’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.87 earnings per share.

COO has been the subject of several research analyst reports. Robert W. Baird reaffirmed a “buy” rating and issued a $345.00 price objective on shares of Cooper Companies in a report on Friday, December 6th. Zacks Investment Research raised shares of Cooper Companies from a “sell” rating to a “hold” rating and set a $325.00 price objective for the company in a report on Wednesday, November 20th. KeyCorp upped their price objective on shares of Cooper Companies from $351.00 to $380.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. Northcoast Research reaffirmed a “buy” rating on shares of Cooper Companies in a report on Tuesday, December 3rd. Finally, Wells Fargo & Co upped their price objective on shares of Cooper Companies from $360.00 to $388.00 and gave the stock an “overweight” rating in a report on Thursday, January 16th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $344.70.

COO stock traded up $0.34 during trading on Tuesday, hitting $353.31. The company had a trading volume of 195,721 shares, compared to its average volume of 284,985. The firm has a market capitalization of $17.47 billion, a price-to-earnings ratio of 37.83, a P/E/G ratio of 2.54 and a beta of 0.89. The business has a 50 day moving average of $341.43 and a 200 day moving average of $316.71. Cooper Companies has a fifty-two week low of $274.77 and a fifty-two week high of $365.68. The company has a current ratio of 1.05, a quick ratio of 0.59 and a debt-to-equity ratio of 0.35.

The firm also recently declared a semi-annual dividend, which was paid on Monday, February 10th. Shareholders of record on Thursday, January 23rd were issued a $0.03 dividend. The ex-dividend date of this dividend was Wednesday, January 22nd. Cooper Companies’s payout ratio is 0.49%.

In other Cooper Companies news, Director Michael Kalkstein sold 9,500 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $320.35, for a total value of $3,043,325.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jody S. Lindell sold 3,500 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $321.01, for a total transaction of $1,123,535.00. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp lifted its position in shares of Cooper Companies by 1.5% in the fourth quarter. State Street Corp now owns 2,114,314 shares of the medical device company’s stock worth $679,308,000 after purchasing an additional 31,882 shares in the last quarter. Veritas Asset Management LLP lifted its position in shares of Cooper Companies by 0.9% in the third quarter. Veritas Asset Management LLP now owns 990,602 shares of the medical device company’s stock worth $294,209,000 after purchasing an additional 9,300 shares in the last quarter. FIL Ltd lifted its position in shares of Cooper Companies by 18.5% in the fourth quarter. FIL Ltd now owns 938,718 shares of the medical device company’s stock worth $301,601,000 after purchasing an additional 146,784 shares in the last quarter. Amundi Pioneer Asset Management Inc. lifted its position in shares of Cooper Companies by 83.5% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 915,089 shares of the medical device company’s stock worth $294,008,000 after purchasing an additional 416,382 shares in the last quarter. Finally, Marshall Wace North America L.P. lifted its position in shares of Cooper Companies by 56.1% in the fourth quarter. Marshall Wace North America L.P. now owns 813,443 shares of the medical device company’s stock worth $261,352,000 after purchasing an additional 292,238 shares in the last quarter. 96.30% of the stock is owned by institutional investors.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Further Reading: Growth Stocks

Get a free copy of the Zacks research report on Cooper Companies (COO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.